Enanta Pharmaceuticals, Inc. (ENTA)
Nasdaq · Healthcare · Biotechnology
$12.60−2.78%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $367M
- 52-week range
- $10.20 – $17.15
- 52-week change
- +14.19%
- EPS (trailing)
- −$2.42
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 16, 2026
Fiscal year to Sep 2025
- Revenue
- $65.3M (−3.42%)
- Net income
- −$81.9M
- Operating margin
- −130.7%
- Diluted EPS
- −$3.84
- Free cash flow
- −$32.2M
From the company’s annual report on SEC EDGAR.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Headquarters: Watertown, United States · 120 employees · enanta.com